TMED1

Across TCGA pan-cancer cohorts, TMED1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMED1 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher TMED1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMED1 expression acts as an unfavorable survival marker.

CESC, SKCM, and UCEC are the cancer types where TMED1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	III,IV	0.091	0.728	<.001	24	view →
SKCM	OS	Median	All	0.216	0.787	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	All	0.235	0.678	.046	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMED1–CESC (DFS)

Open the CESC breakdown →